B+
Bull case
25%
Probability
Target price
$45.66
Analysis reference price unavailable
Analysis 2025-12-07 · RankAlpha Sentiment AI
INDV
IndiviorCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
50%
Probability
Target price
$33.36
Analysis reference price unavailable
Analysis 2025-12-07 · RankAlpha Sentiment AI
B-
Bear case
25%
Probability
Target price
$26.34
Analysis reference price unavailable
Analysis 2025-12-07 · RankAlpha Sentiment AI
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2025-12-07
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+62.8
Score
AI commentary
Market tone is cautious-to-neutral: official close data show a mid-$30s anchor and investors are monitoring earnings and commercial cadence for direction [#RA-2025-12-05]. Short-term chatter focuses on reimbursement and litigation risk, while longer-term sentiment hinges on sustained U.S. uptake [#RA-2025-12-05]. Overall, headlines currently favor a watchful stance rather than outright conviction.
RankAlpha Sentiment AI - 2025-12-07
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
-eventQuarterly earnings / updated guidanceHigh impact
Quarterly results and management commentary can reprice expectations for margins and US commercial momentum; typical headline mover for INDV [#RA-2025-12-05].
-catalystRegulatory, litigation, or generic-entry shockHigh impact
Adverse regulatory decisions or faster-than-expected generic competition could cause sharp downside; historically a material risk for specialty pharma names [#RA-2025-12-05].
-catalystCommercial uptake / market-share gains for core OUD productsHigh impact
Sustained volume growth or better payer coverage for Indivior's opioid-use-disorder (OUD) franchise would support upside vs. peers; impact depends on US formulary trends [#RA-2025-12-05].
Recommendation
N/A
No formal recommendation provided.
As of 2025-12-07 • Updated nightlySource: Internal modelMethodology